Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.43 |
| ▸ | CNR2 | P34972 | 13/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807832 | 0.88 | CNR1 (0.40) | CNR1CNR2CYP2C9 | |
| SCHEMBL4801849 | 0.88 | CNR1 (0.48) | CNR1CNR2CDC7DBF4CCNE1 | |
| SCHEMBL4809553 | 0.87 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL14107195 | 0.85 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL4807867 | 0.85 | CNR1 (0.39) | CNR1CNR2CYP2C9 | |
| SCHEMBL4807053 | 0.77 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL4807617 | 0.75 | PTGS2 (0.38) | CNR1CNR2 | |
| SCHEMBL4801891 | 0.75 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL14107184 | 0.74 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL4807100 | 0.74 | CNR1 (0.47) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405221-B2 | Substituted pyrimidines | MERCK & CO., INC. (US) | 2008-07-29 | — | — | US | claimed |
| US-20050245554-A1 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | claimed |
| US-7405221-B2 | Substituted pyrimidines | MERCK & CO., INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050245554-A1 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
| EP-1546115-A2 | SUBSTITUTED PYRIMIDINES | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029204-A2 | SUBSTITUTED PYRIMIDINES | MERCK & CO., INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245554-A1 | Substituted pyrimidines | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885CDC7 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.